Morningstar

Novartis to Buy Myricx Bio for Up to $1.5 Billion

Provided by Dow Jones

By Aimee Look 




  Novartis said it agreed to pay up to $1.5 billion for Myricx Bio to bolster its oncology capabilities. 



  The Swiss pharmaceutical company said it would purchase the privately held U.K.-based biotechnology firm, which is developing a new class of antibody-drug conjugates. Myricx Bio's approach delivers differentiated cancer-killing mechanisms directly to tumor cells, Novartis said. 



  Novartis will pay $1.1 billion upfront, with up to $400 million in potential additional payments. The deal, expected to close in the second half of 2026, is subject to regulatory approvals. 





  Write to Aimee Look at aimee.look@wsj.com 





  Corrections & Amplifications


  



  This article was corrected at 0616 GMT to reflect that Novartis will pay up to $400 million in potential additional payments. The original article incorrectly stated that figure as $400. 



  (END) Dow Jones Newswires



  July 06, 2026 01:38 ET (05:38 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
 
Ask the Analyst columnist Amy Arnott answers a grab bag of reader questions about bond ETFs, TIPS, retirement planning, and more. 
 
 
Amy C. Arnott, CFA and Ivanna Hampton 
 
 
 
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
 
With a 3.3% dividend yield and earnings growth expected to exceed management’s outlook, this 4-star stock stands out in a struggling sector. 
 
 
Andrew Bischof, CFA, CPA 
 
 
 
The Thrilling 37
 
Just a few strict screens can narrow the field to an elite group of funds. 
 
 
Russel Kinnel 
 
 
 
The 10 Best and 10 Worst Months of All Time for the US Stock Market
 
Do common investor sayings about particular months being stronger or weaker for stocks have empirical backing, or is it all market mythology? Dan Lefkovitz uncovered some surprising truths about stock market performance by examining over 100 years of data. 
 
 
Dan Lefkovitz 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
 

			Sponsor Center